Survey about tolerance of the AS03-adjuvanted H1N1 influenza vaccine in children with rheumatic diseases

被引：6
|
作者：
Sengler, C. [1 ]
Niewerth, M. [1 ]
Kallinich, T. [2 ]
Nimtz-Talaska, A.
Haller, M.
Huppertz, H. -I. [3 ]
Minden, K. [1 ]
机构：
[1] German Rheumatism Res Ctr Berlin, Leibniz Inst, Epidemiol Unit, D-10117 Berlin, Germany
[2] Charite, Childrens Univ Hosp, Dept Pediat Pneumol & Immunol, D-13353 Berlin, Germany
[3] Klinikum Bremen Mitte, Bremen, Germany
来源：
CLINICAL RHEUMATOLOGY | 2014年 / 33卷 / 01期
关键词：
Children; Disease activity; Flare; H1N1 influenza vaccination; Rheumatic disease; JUVENILE IDIOPATHIC ARTHRITIS; SAFETY; IMMUNOGENICITY;
D O I：
10.1007/s10067-013-2435-8
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
The objective of this study is to evaluate complications and changes in health status (disease activity and flare) in response to the AS03-adjuvanted H1N1 vaccine in children with rheumatic diseases. We conducted a nationwide survey addressing paediatric rheumatology sites who participated in the national paediatric rheumatology database. Ninety patients were documented-38 % under treatment with biologicals-of whom 18 % suffered from complications (10 % local and 8 % systemic) with no relevant changes in median disease activity or flare rate during 4 weeks following the vaccination. The adjuvanted H1N1 influenza vaccine seems to be adequately tolerated in children with rheumatic diseases.
引用
收藏
页码：137 / 139
页数：3
相关论文
共 50 条
  • [41] Immunogenicity of pandemic influenza A H1N1/2009 adjuvanted vaccine in pediatric solid organ transplant recipients
    Gavalda, J.
    Cabral, E.
    Perez-Romero, P.
    Len, O.
    Aydillo, T.
    Campins, M.
    Quintero, J.
    Peghin, M.
    Nieto, J.
    Charco, R.
    Pahissa, A.
    Cordero, E.
    PEDIATRIC TRANSPLANTATION, 2013, 17 (04) : 403 - 406
  • [42] Assessment of squalene adjuvanted and non-adjuvanted vaccines against pandemic H1N1 influenza in children 6 mo to 17 y of age
    Vesikari, Timo
    Pepin, Stephanie
    Kusters, Inca
    Hoffenbach, Agnes
    Denis, Martine
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2012, 8 (09) : 1283 - 1292
  • [43] Assessment of Prime-boost Vaccination Using an AS03B-adjuvanted Influenza A (H5N1) Vaccine
    Izurieta, Patricia
    Jeane Uy-Aragon, Mercy
    Drame, Mamadou
    Vaughn, David W.
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2016, 35 (02) : E35 - E47
  • [44] Clinical and Immune Responses to Inactivated Influenza A(H1N1)pdm09 Vaccine in Children
    Kotloff, Karen L.
    Halasa, Natasha B.
    Harrison, Christopher J.
    Englund, Janet A.
    Walter, Emmanuel B.
    King, James C.
    Creech, C. Buddy
    Healy, Sara A.
    Dolor, Rowena J.
    Stephens, Ina
    Edwards, Kathryn M.
    Noah, Diana L.
    Hill, Heather
    Wolff, Mark
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2014, 33 (08) : 865 - 871
  • [45] Did narcolepsy occur following administration of AS03-adjuvanted A(H1N1) pandemic vaccine in Ontario, Canada? A review of post-marketing safety surveillance data
    Harris, T.
    Wong, K.
    Stanford, L.
    Fediurek, J.
    Crowcroft, N.
    Deeks, S. L.
    EUROSURVEILLANCE, 2014, 19 (36): : 18 - 22
  • [46] A Novel Influenza A (H1N1) Vaccine in Various Age Groups.
    Zhu, Feng-Cai
    Wang, Hua
    Fang, Han-Hua
    Yang, Jian Guo
    Lin, Xiao Jun
    Liang, Xiao-Feng
    Zhang, Xue-Feng
    Pan, Hong-Xing
    Meng, Fan-Yue
    Hu, Yue Mei
    Liu, Wen-Dong
    Li, Chang-Gui
    Li, Wei
    Zhang, Xiang
    Hu, Jin Mei
    Peng, Wei Bing
    Yang, Bao Ping
    Xi, Pei
    Wang, Hua-Qing
    Zheng, Jing-Shan
    NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (25) : 2414 - 2423
  • [47] Characterization and long-term persistence of immune response following two doses of an AS03A-adjuvanted H1N1 influenza vaccine in healthy Japanese adults
    Ikematsu, Hideyuki
    Nagai, Hideaki
    Kawashima, Masahiro
    Kawakami, Yasunobu
    Tenjinbaru, Kazuyoshi
    Li, Ping
    Walravens, Karl
    Gillard, Paul
    Roman, Francois
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2012, 8 (02)
  • [48] Safety of AS03-adjuvanted inactivated split virion A(H1N1)pdm09 and H5N1 influenza virus vaccines administered to adults: Pooled analysis of 28 clinical trials
    Vaughn, David W.
    Seifert, Harry
    Hepburn, Anne
    Dewe, Walthere
    Li, Ping
    Drame, Mamadou
    Cohet, Catherine
    Innis, Bruce L.
    Fries, Louis F.
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2014, 10 (10) : 2942 - 2957
  • [49] Humoral and cellular responses to a non-adjuvanted monovalent H1N1 pandemic influenza vaccine in hospital employees
    Teresa Herrera, Ma
    Gonzalez, Yolanda
    Juarez, Esmeralda
    Hernandez-Sanchez, Fernando
    Carranza, Claudia
    Sarabia, Carmen
    Guzman-Beltran, Silvia
    Eugenia Manjarrez, Ma
    Munoz-Torrico, Marcela
    Garcia-Garcia, Lourdes
    Sada, Eduardo
    Torres, Martha
    BMC INFECTIOUS DISEASES, 2013, 13
  • [50] An adjuvanted pandemic influenza H1N1 vaccine provides early and long term protection in health care workers
    Madhun, Abdullah S.
    Akselsen, Per Espen
    Sjursen, Haakon
    Pedersen, Gabriel
    Svindland, Signe
    Nostbakken, Jane Kristin
    Nilsen, Mona
    Mohn, Kristin
    Jul-Larsen, Asne
    Smith, Ingrid
    Major, Diane
    Wood, John
    Cox, Rebecca J.
    VACCINE, 2010, 29 (02) : 266 - 273
12345